摘要
目的:观察重组人血管内皮抑素(恩度)联合化疗药物治疗晚期消化道肿瘤的疗效和安全性。方法:经病理证实的晚期消化道肿瘤患者65例,实验组32例采用恩度加化疗的一线治疗方法,对照组33例采用常规化疗的治疗方法,均治疗2-4个周期。按照RECIST标准和WHO毒性反应分级标准评价疗效,由KPS评分变化评价患者生活质量改善及药物毒性反应。结果:实验组32例晚期消化道患者中,CR 1例,PR 7例,SD15例,PD 9例,总有效率25.0%,疾病控制率71.9%,生活质量改善率78.1%;中位至疾病进展时间(mTTP)6.4个月,中位总生存期(OS)12.1个月,对照组33例中,CR 0例,PR 6例,SD 13例,PD 14例,总有效率18.2%,疾病控制率57.6%,生活质量改善率63.5%,中位至疾病进展时间(mTTP)5.1个月,中位总生存期(OS)10.5个月;两组间疗效差异有显著性(P<0.05)、生活质量改善率两组差异有统计学意义P<0.05。毒性反应主要为骨髓抑制及胃肠道反应和轻度心电图改变等。结论:恩度联合化疗治疗晚期消化道肿瘤的客观疗效好,安全性好,毒性低,可以改善患者的生活质量,值得进一步推广使用。
Objective:To observe the efficacy and safety of recombinant human endostatin(ex) combined with chemotherapy in the treatment of advanced digestive cancer.Methods:Total of 65 cases with advanced digestric cancer were involved in the study.Research group 32 cases were treated with recombinant human endostatin(ex) combined with chemotherapy,control group 33 cases were treated with chemotherapy with two cycles.According to RECIST criteria and WHO toxicity classification standards,and KPS score to evaluate the curative effect and patients' quality of life improvement,drug toxicity.Results:Among research group 32 cases,there were CR 1 cases PR 7 cases,SD15 cases,PD 9 cases,overall response rate was 25%,disease control rate was 71.9%,life quality improve rate was 78.1%,median time to disease progression(mTTP) 6.4 months,median overall survival(OS) 12.1 months;Among controlled group 33 cases,there were CR 0 cases PR 6 cases,SD13 cases,PD 14 cases,overall response rate was 18.2%,disease control rate was 57.6%,life quality improve rate was 63.5%,median time to disease progression(mTTP) 5.1 months,median overall survival(OS) 10.5months;The difference of efficacy between the two groups was significant(P 0.0 5).Quality of life improvement rate was statistically significant between the two groups P 0.05.The main toxicity reaction included marrow depression,gastrointestinal tract reaction and mild ECG change.Conclusion:Endostar combined with chemotherapy in the treatment of advanced gastrointestinal cancer is an effective and safe regimen.
出处
《现代肿瘤医学》
CAS
2012年第3期570-572,共3页
Journal of Modern Oncology